NEW YORK, Sept. 29, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board. Dr. Roth has spent over 30 years studying molecular neuropharmacology. He is the Michael Hooker Distinguished…


Previous articleMDMA: A Catalyst for ED-PTSD Treatment
Next articlePsychedelics and Pregnancy: A Look Into the Safety, Research and Legality